计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| I129798-50mg |
50mg |
现货 ![]() |
| |
| I129798-100mg |
100mg |
现货 ![]() |
| |
| I129798-250mg |
250mg |
现货 ![]() |
| |
| I129798-500mg |
500mg |
现货 ![]() |
| |
| I129798-1g |
1g |
现货 ![]() |
| |
| I129798-5g |
5g |
现货 ![]() |
| |
| I129798-25g |
25g |
现货 ![]() |
|
| 别名 | 咪喹莫特 | 1-(2-甲基丙基)-1 H -咪唑 4,5- c 喹啉-4-胺 | 1-(2-甲基丙基)-4-氨基-1H-咪唑并[4,5-c]喹啉 | 1-异丁基-1H-咪唑[4.5-C]喹啉-4-胺基 | 4-氨基-1-异丁基-1H-咪唑并[4,5-c]喹啉 |
|---|---|
| 英文别名 | HMS3715N19 | Imiquimod 100 microg/mL in Acetonitrile | Imiquimod- Bio-X | Aldara (TN) | DTXSID7041047 | HY-B0180 | S 26308 | AB00399298-05 | IMIQUIMOD [ORANGE BOOK] | YH44175 | 1-isobutylimidazo[4,5-c]quinolin-4-amine | HB3109 | IMIQUIMOD [JAN] | 4-Amino- |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Imiquimod |
| 生化机理 | 咪喹莫特是咪唑喹啉胺的衍生物,可抑制血管生成,是一种免疫反应调节剂。有研究报告称,咪喹莫特能够抑制转移和诱导α-干扰素(IFN-α)。此外,咪喹莫特还是一种TLR7(toll样受体7)激动剂,可诱导浆细胞树突状细胞(pDC)成熟。咪喹莫特作用于表达 TLR7 的树突状细胞,诱导免疫反应。核因子-B有助于介导咪喹莫特的活性,并参与提高趋化因子和细胞因子的水平。研究表明,Imiquimod 的抗血管生成特性是由 IL-18 介导的。研究表明,咪喹莫特能诱导癌细胞凋亡。还被证实是一种 Caspase-3 和 NFκB 的激活剂。激活 NF-κB,刺激促炎细胞因子。免疫调节剂、抗病毒剂和抗肿瘤剂。在体内和体外均有活性。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 激动剂 |
| 作用机制 | TLR7 激动剂 |
| 备注 | 如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的密封小瓶中。通常,它们最多可以使用一个月。在使用前和打开样品瓶之前,我们建议您让您的产品在室温下平衡至少1小时。有毒,请参阅SDS以获取更多信息。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
| 产品介绍 |
Product Description Imiquimod (R 837) is an immune response modifier that acts as a toll-like receptor 7 agonist. Product Application Imiquimod is a caspase 3 activator which acts as an immunomodulator and displays antiviral and anti-tumor activity. It is a patient-applied cream used for the treatment of genital warts and basal cell carcinoma. It is also used to cure actinic keratosis on the face and scalp. It belongs to a group of drugs called immune response modifiers, which work by activating the immune system to fight abnormal skin growth. |
| 纯度 | ≥98% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 488183396 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine |
| INCHI | 1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17) |
| InChi Key | DOUYETYNHWVLEO-UHFFFAOYSA-N |
| Smiles | CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N |
| Isomeric SMILES | CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N |
| 分子量 | 240.31 |
| Reaxy-Rn | 7710060 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=7710060&ln= |
| 溶解性 | Soluble in DMSO (4 mg/ml ,warming to 60 °C for 15 minutes) DMF (1.5 mg/ml) at 37 °C, and water (slightly soluble) at 37 °C. Insoluble in ethanol. |
|---|---|
| 熔点 | 297~299℃ |
| 分子量 | 240.300 g/mol |
| XLogP3 | 2.600 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 3 |
| 可旋转键计数Rotatable Bond Count | 2 |
| 精确质量Exact Mass | 240.137 Da |
| 单同位素质量Monoisotopic Mass | 240.137 Da |
| 拓扑极表面积Topological Polar Surface Area | 56.700 Ų |
| 重原子数Heavy Atom Count | 18 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 294.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | I129798 | |
| 分析证书 | I129798 | |
| 分析证书 | I129798 | |
| 分析证书 | I129798 | |
| 分析证书 | I129798 | |
| 分析证书 | I129798 | |
| 分析证书 | I129798 | |
| 分析证书 | I129798 | |
| 分析证书 | I129798 | |
| 分析证书 | I129798 | |
| 分析证书 | I129798 | |
| 分析证书 | I129798 | |
| 分析证书 | I129798 | |
| 分析证书 | I129798 | |
| 分析证书 | I129798 | |
| 分析证书 | I129798 | |
| 分析证书 | I129798 | |
| 分析证书 | I129798 | |
| 分析证书 | I129798 | |
| 分析证书 | I129798 | |
| 分析证书 | I129798 | |
| 分析证书 | I129798 | |
| 分析证书 | I129798 |
| 1. Haifeng Ni, Sunxiang Qian, Jie Lu, Jie Feng, Xiao-zhou Mou, Jing Zhang. (2023) Natural Polysaccharide Delivery Platforms with Multiscale Structure Used for Cancer Chemoimmunotherapy. MOLECULAR PHARMACEUTICS, [PMID:37752866] [10.1021/acs.molpharmaceut.3c00633] |
| 2. Lu Dehua, Xu Yanming, Yang Xiaodong, Li Ying, Li Mengqing, Zheng Yuanyuan, Wang Yuenan, Wang Weihu, Wang Shubin, Gao Jing, Liu Yajie. (2023) Neutrophil membrane-derived nanoparticle loading TLR7 agonists augments radiotherapy efficacy and boosts abscopal effect via regulating tumor microenvironment. Cancer Nanotechnology, 14 (1): (1-18). [10.1186/s12645-023-00193-8] |
| 3. Hong Liu, Zhenfu Wen, Haolin Chen, Zeyu Yang, Zhicheng Le, Zhijia Liu, Yongming Chen, Lixin Liu. (2022) Nanoadjuvants Actively targeting lymph node conduits and blocking tumor invasion in lymphatic vessels. JOURNAL OF CONTROLLED RELEASE, 352 (497). [PMID:36341931] [10.1016/j.jconrel.2022.10.053] |
| 4. Meiting Li, Yaqian Zhang, Xiaoge Zhang, Zhuoyin Liu, Junjie Tang, Miao Feng, Baizhu Chen, Dalin Wu, Jie Liu. (2022) Degradable Multifunctional Porphyrin-Based Porous Organic Polymer Nanosonosensitizer for Tumor-Specific Sonodynamic, Chemo- and Immunotherapy. ACS Applied Materials & Interfaces, 14 (43): (48489–48501). [PMID:36281484] [10.1021/acsami.2c14776] |
| 5. Jiexin Li, He Ren, Yaping Sun, Gengqi Liu, Xingyue Yang, Qian Qiu, Yuanmeng Ding, Jonathan F. Lovell, Yumiao Zhang. (2021) Magnetic Metal Micelles for Enhanced Delivery of Self-Immolating CD8+ T-Cell Epitopes for Cancer Immunotherapy. CHEMISTRY OF MATERIALS, 33 (24): (9780–9794). [10.1021/acs.chemmater.1c03681] |
| 6. Lili Cheng, Xiaoge Zhang, Junjie Tang, Qijun Lv, Jie Liu. (2021) Gene-engineered exosomes-thermosensitive liposomes hybrid nanovesicles by the blockade of CD47 signal for combined photothermal therapy and cancer immunotherapy. BIOMATERIALS, 275 (120964). [PMID:34147721] [10.1016/j.biomaterials.2021.120964] |
| 7. Zhang Lirong, Zhang Jingjing, Xu Lixia, Zhuang Zijian, Liu Jingjin, Liu Suwan, Wu Yunchao, Gong Aihua, Zhang Miaomiao, Du Fengyi. (2021) NIR responsive tumor vaccine in situ for photothermal ablation and chemotherapy to trigger robust antitumor immune responses. JOURNAL OF NANOBIOTECHNOLOGY, 19 (1): (1-16). [PMID:34001148] [10.1186/s12951-021-00880-x] |
| 8. Yuting Cao, Yan Zhou, Jinbin Pan, Xinyu Zhong, Jianmin Ding, Xiang Jing, Shao-Kai Sun. (2021) A general strategy towards an injectable microwave-sensitive immune hydrogel for combined percutaneous microwave ablation and immunotherapy. CHEMICAL ENGINEERING JOURNAL, 422 (130111). [10.1016/j.cej.2021.130111] |
| 9. Fan Jiang, Binbin Ding, Shuang Liang, Yajie Zhao, Ziyong Cheng, Bengang Xing, Ping'an Ma, Jun Lin. (2021) Intelligent MoS2–CuO heterostructures with multiplexed imaging and remarkably enhanced antitumor efficacy via synergetic photothermal therapy/ chemodynamic therapy/ immunotherapy. BIOMATERIALS, 268 (120545). [PMID:33253965] [10.1016/j.biomaterials.2020.120545] |
| 10. Zhaocheng Li, Jiyuan Gao, Zexing Xiang, Honglei Zhang, Yibei Wang, Xuefei Zhang. (2020) A pH-responsive polymer linked with immunomodulatory drugs: synthesis, characteristics and in vitro biocompatibility. JOURNAL OF APPLIED TOXICOLOGY, 41 (5): (724-735). [PMID:32776438] [10.1002/jat.4042] |
| 11. Xiangbo Meng, Ke Wang, Lin Lv, Ye Zhao, Chen Sun, Lianjun Ma, Bin Zhang. (2019) Photothermal/Photodynamic Therapy with Immune-Adjuvant Liposomal Complexes for Effective Gastric Cancer Therapy. PARTICLE & PARTICLE SYSTEMS CHARACTERIZATION, 36 (6): (1900015). [10.1002/ppsc.201900015] |
| 12. Shiquan Sun, Yong He, Jiaqi Xu, Shaolong Leng, Yu Liu, Huanhuan Wan, Leping Yan, Yunsheng Xu. (2024) Enhancing cell pyroptosis with biomimetic nanoparticles for melanoma chemo-immunotherapy. JOURNAL OF CONTROLLED RELEASE, 367 (470). [PMID:38290565] [10.1016/j.jconrel.2024.01.057] |
| 13. Guangchao Xie, Bingjie Li, Shuyue Guo, Wenjing Hou, Yao Wang, Jiamei Liu, Jialin Zhu, Luchen Chang, Xiaoqing Wang, Xiaoyi Wang, Jinbin Pan, Xi Wei. (2025) Minimalistic Implant for Percutaneous Magnetic Hyperthermia-Based Combination Therapy of Hepatocellular Carcinoma. ACS Applied Materials & Interfaces, 17 (7): (10369-10379). [PMID:39916295] [10.1021/acsami.4c18486] |
| 14. Siqiong Wu, Yongjun Chen, Ke Wang, Mingquan Huang, Liuxuan Yang, Jing Yang, Qiming Wei, Chao Tao, Chunhong Li, Meiling Zhou. (2025) Multifunctional mesoporous polydopamine nanoplatforms for synergistic photothermal-chemotherapy and enhanced immunotherapy in breast cancer treatment. COLLOIDS AND SURFACES B-BIOINTERFACES, 248 (114483). [PMID:39740488] [10.1016/j.colsurfb.2024.114483] |
| 15. Guangchao Xie, Bingjie Li, Xuejun Zhang, Jiaojiao Yu, Shao-Kai Sun. (2024) One-Minute Preparation of Iron Foam-Drug Implant for Ultralow-Power Magnetic Hyperthermia-Based Combination Therapy of Tumors in Vivo. Advanced Science, 11 (11): (2307823). [PMID:38164827] [10.1002/advs.202307823] |
| 16. Siqi Geng, Baoru Fang, Ke Wang, Fang Wang, Yiqing Zhou, Yike Hou, M. Zubair Iqbal, Yanping Chen, Zhangsen Yu. (2024) Polydopamine Nanoformulations Induced ICD and M1 Phenotype Macrophage Polarization for Enhanced TNBC Synergistic Photothermal Immunotherapy. ACS Applied Materials & Interfaces, 16 (44): (59814-59832). [PMID:39450881] [10.1021/acsami.4c11594] |